文献速递药物相互作用治疗药物监测与药物基因组学

阿卡替尼CYP3A介导的药物相互作用:临床评价与PBPK建模指导剂量调整策略

Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
PubMed 文献 · Br J Clin Pharmacol · 2022-03-28

本研究通过开放标签随机两周期试验,考察氟康唑或艾沙康唑对阿卡替尼及其活性代谢物ACP-5862药代动力学的影响,并对比PBPK模型模拟结果。结果显示两种中度CYP3A抑制剂升高阿卡替尼暴露、降低ACP-5862暴露,但BTK受体占有率变化极小,仅报告1级不良事件,提示无需调整剂量。

要点

  • 氟康唑使阿卡替尼AUC升高2.16倍,艾沙康唑升高1.60倍。
  • 两种抑制剂均降低ACP-5862暴露,但BTK占有率变化极小。
  • 仅报告1级不良事件,无严重不良事件或停药,支持无需调整剂量。

核心结论

  • 氟康唑和艾沙康唑影响阿卡替尼及ACP-5862的药代动力学,但建议与中度CYP3A抑制剂联用时无需调整剂量。
  • 当前PBPK模型可用于提出经CYP3A介导的药物相互作用的剂量调整建议。

研究设计与样本

  • 开放标签、随机、两周期临床研究,考察氟康唑或艾沙康唑对阿卡替尼药代动力学的影响,并与PBPK模拟结果比较。

主要发现

  • 艾沙康唑联用时阿卡替尼Cmax和AUC的几何最小二乘均值分别升高1.37(1.14-1.64)倍和1.60(1.45-1.77)倍。
  • 氟康唑联用时阿卡替尼Cmax和AUC分别升高1.48(1.10-1.98)倍和2.16(1.94-2.40)倍。
  • 艾沙康唑联用时ACP-5862的Cmax和AUC分别变为0.72(0.63-0.82)倍和0.91(0.86-0.97)倍。
  • 氟康唑联用时ACP-5862的Cmax和AUC分别变为0.65(0.49-0.87)倍和0.95(0.91-0.99)倍。
  • PBPK模型能重现研究中阿卡替尼和ACP-5862的药代动力学特征,艾沙康唑联用时BTK受体占有率变化极小。

临床怎么用

  • 临床药师可依据本研究结果,在与中度CYP3A抑制剂(如氟康唑、艾沙康唑)联用时无需调整阿卡替尼剂量。

局限性

  • 本研究仅报告1级不良事件,发生率17%,未观察到死亡、严重不良事件或因不良事件停药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Clinical drug interaction studies with itraconazole and rifampicin have demonstrated that acalabrutinib is a sensitive substrate of CYP3A. A physiologically based pharmacokinetic (PBPK) model was developed based on the data of these studies. One of the active CYP3A metabolites, ACP-5862, was identified but never studied in a drug interaction scenario. This study aims to evaluate both parent and metabolite exposure change with coadministration of moderate CYP3A inhibitors and its impact on safety and efficacy. METHODS: In an open label, randomized, 2-period study, we investigated the effect of coadministration of fluconazole or isavuconazole on the pharmacokinetics of acalabrutinib. Bruton tyrosine kinase receptor occupancy and safety were compared between different treatments. Experimental data were compared to PBPK simulation results. RESULTS: Least square means of acalabrutinib maximum plasma concentration and area under the curve increased 1.37 (1.14-1.64) and 1.60 (1.45-1.77)-fold in the presence of isavuconazole and 1.48 (1.10-1.98) and 2.16 (1.94-2.40)-fold in the presence of fluconazole, respectively. For ACP-5862, these values are 0.72 (0.63-0.82) and 0.91 (0.86-0.97) fold for isavuconazole and 0.65 (0.49-0.87) and 0.95 (0.91-0.99) fold for fluconazole coadministration. The PBPK model was able to recover acalabrutinib and ACP-5862 PK profiles in the study. Bruton tyrosine kinase receptor occupancy change was minimal in the presence of isavuconazole. There were no deaths, serious adverse events (AEs), or subject discontinuation due to AEs in this study. Only mild (Grade 1) AEs were reported during the study, by 17% of the study population. CONCLUSION: Our results demonstrate the impact of fluconazole and isavuconazole on the pharmacokinetics of acalabrutinib and ACP-5862, and suggest that no dose adjustment is needed for concomitant administration with moderate CYP3A inhibitors. the current PBPK model can be used to propose dose adjustment for drug interactions via CYP3A.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chen B, Zhou D, Wei H, et al. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. Br J Clin Pharmacol. 2022. PMID: 35165925. doi:10.1111/bcp.15278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。